NDAORALTABLET, EXTENDED RELEASE
Approved
Aug 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CLARITIN-D 24 HOUR (loratadine and pseudoephedrine sulfate) by Bayer. Approved for these symptoms due to hay fever, other upper respiratory allergies: sneezing itchy, watery eyes runny nose itching of the nose and 4 more indications. First approved in 1996.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Claritin-D 24 Hour is an oral extended-release tablet combining loratadine (a non-sedating antihistamine) and pseudoephedrine sulfate (a nasal decongestant) for symptomatic relief of allergic rhinitis and upper respiratory congestion. It treats sneezing, itchy/watery eyes, runny nose, nasal congestion, and sinus pressure associated with hay fever and common colds. The dual mechanism addresses both allergic symptoms and congestion in a single daily dose.
LOE Approaching
This product faces approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team focus is shifting toward generic defense, lifecycle extension, or transition to newer pipeline products.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CLARITIN-D 24 HOUR at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.